Company
Headquarters: Seoul, South Korea
Employees: 2,155
CEO: Mr. Jong-Soo Woo Ph.D.
₩5.617 Trillion
KRW as of Jan. 1, 2026
US$3.89 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Hanmi Pharm. Co., Ltd. operates as a pharmaceutical company worldwide. It develops treatments for diabetes, obesity, cancer, autoimmune, and rare diseases. The company was founded in 1973 and is based in Seoul, South Korea.
| Last Financial Reports Date | Sept. 30, 2025 |
| Revenue TTM | ₩1.466 T |
| EBITDA | ₩298.33 B |
| Gross Profit TTM | ₩809.17 B |
| Profit Margin | 7.95% |
| Operating Margin | 14.42% |
| Quarterly Revenue Growth | 0.10% |
Hanmi Pharm. Co. Ltd has the following listings and related stock indices.
Stock: KRX: 128940 wb_incandescent